Particularly poor prognoses are associated with high‐grade B‐cell lymphoma (HGBL), which is characterized by MYC and BCL2 and/or BCL6 rearrangements.[2] Ongoing clinical trials for BCL, especially for aggressive HGBL, require further validation. The gene discussed is MYC; the disease is high grade B-cell lymphoma.